The addition of IMPAC enhances Consorta’s existing relationship with Elekta, whose contract originated in May 2004 and includes the revolutionary Elekta Synergy^® treatment delivery series.  Consorta also has an agreement with Elekta for PrecisePlan® treatment planning systems stereotactic neurosurgical and radiosurgery products, including Leksell Gamma Knife^®. With the addition of IMPAC to the Elekta contract, all of Consorta’s current and future radiation oncology equipment will fully support EMR-based image-guided radiotherapy (IGRT), thereby providing optimized clinical workflow processing and a central repository for oncology data and images. Additional fully integrated features, such as department scheduling, on and off line transcription, automated procedure capture and audit, medical billing and A/R, and management reporting, provide a comprehensive process management solution for the entire cancer care team –whether in one location or in multiple sites.

“IMPAC’s open architecture and flexibility bring great value to Consorta members who operate not only Elekta Oncology products but all other manufacturers as well.  The ability to use as many or as few of the IMPAC components gives our members the value and flexibility they need.  We are very pleased to offer this comprehensive management solution to our membership”, said Dan Ingram, Director of Imaging Services for Consorta. 

While Consorta customers will take advantage of IMPAC’s vendor-independent support for radiation therapy delivery, the new joint IMPAC/Elekta agreement does ensure added value for members who opt for a combined solution. IMPAC’s best-of-breed oncology EMR combined with Elekta’s clinically-proven IGRT technology, results in the most streamlined image-guided treatment management (IGTM™) solution currently available.  

“We are extremely excited to have entered into an agreement with Consorta,” states James Hoey, President and CEO, IMPAC Medical Systems Inc. “This partnership assures that members of Consorta, will have immediate access to IMPAC’s wide breadth of IT solutions that not only preserves the value of their installed treatment and planning equipment investment, but also takes complete advantage of Elekta’s new IGRT equipment. Together this platform comprises the most advanced, comprehensive solution for radiation therapy available in the industry.”

********

For more information, please contact:

Lorna Murdock, Marketing Communications Manager
IMPAC Medical Systems, Inc.
Tel: +1 650-623-8937, e-mail: lmurdock@impac.com

Product Inquiries:

Kim R. Auerbach, National Accounts Manager, IMPAC Medical Systems, Inc.,
Tel: +1 650-623-3864, e-mail: kauerbach@impac.com

Investor Enquiries:

International: Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000, e-mail: peter.ejemyr@elekta.com

United States: Lars Jonsteg, VP Investor Relations North America, Elekta Inc.
Tel: +46 708-783 735, e-mail: lars.jonsteg@elekta.com

Consorta Inquiries:
 
Dan Ingram, Director, Imaging Services, Consorta Inc.
Tel: +1 847-592-7852, e-mail: dingram@consorta.com

About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc., an Elekta company, provides healthcare information technology (IT) solutions that streamline clinical and business operations across the spectrum of cancer care. IMPAC’s open integration to multiple healthcare data and imaging systems offers oncology-specific patient charting and practice management, as well as best-of-breed systems for anatomic pathology, clinical laboratory, and cancer registry. With products that are used in association with diagnosis and treatment environments through long-term follow-up, IMPAC provides a comprehensive oncology management solution that helps improve overall communication, process efficiency, and the quality of patient care. For more information about IMPAC products and services, please call 888-GO-IMPAC or visit www.impac.com.

About Elekta
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta’s solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. With approx. 1700 employees, Elekta’s corporate headquarters is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta’s products or services, please visit www.elekta.com..